Captrust Financial Advisors Has $940,000 Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Captrust Financial Advisors boosted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 31.3% in the fourth quarter, Holdings Channel reports. The firm owned 14,307 shares of the biotechnology company’s stock after purchasing an additional 3,407 shares during the quarter. Captrust Financial Advisors’ holdings in BioMarin Pharmaceutical were worth $940,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Algert Global LLC bought a new position in shares of BioMarin Pharmaceutical in the 4th quarter valued at about $2,767,000. AXA S.A. boosted its position in BioMarin Pharmaceutical by 1.6% during the fourth quarter. AXA S.A. now owns 571,538 shares of the biotechnology company’s stock valued at $37,567,000 after purchasing an additional 8,874 shares during the last quarter. Wahed Invest LLC grew its stake in BioMarin Pharmaceutical by 6.5% in the fourth quarter. Wahed Invest LLC now owns 4,881 shares of the biotechnology company’s stock valued at $321,000 after purchasing an additional 297 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its stake in BioMarin Pharmaceutical by 121.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 18,103 shares of the biotechnology company’s stock valued at $1,190,000 after purchasing an additional 9,915 shares in the last quarter. Finally, PDT Partners LLC increased its position in shares of BioMarin Pharmaceutical by 168.4% during the 4th quarter. PDT Partners LLC now owns 88,663 shares of the biotechnology company’s stock worth $5,828,000 after purchasing an additional 55,635 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,295 shares of BioMarin Pharmaceutical stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total value of $92,618.40. Following the completion of the sale, the chief accounting officer now owns 16,955 shares in the company, valued at $1,212,621.60. The trade was a 7.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders have sold 2,912 shares of company stock worth $202,244. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. StockNews.com raised BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Friday, April 25th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $70.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. The Goldman Sachs Group cut their price target on shares of BioMarin Pharmaceutical from $124.00 to $104.00 and set a “buy” rating for the company in a research note on Monday, May 5th. Bank of America boosted their price objective on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $90.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Seven investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $93.45.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $58.27 on Friday. The firm has a market cap of $11.17 billion, a P/E ratio of 26.49, a price-to-earnings-growth ratio of 0.61 and a beta of 0.27. The business’s 50 day moving average is $63.85 and its 200-day moving average is $65.13. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical Inc. has a 1-year low of $52.93 and a 1-year high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. The firm had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. Equities research analysts predict that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.